Comparison of the iStent Inject® versus the iStent Inject® W—Both in Combination with Cataract Surgery—In Open-Angle Glaucoma
We compare the short- and mid-term postoperative outcomes of the iStent inject® with its successor, the iStent inject® W. A retrospective monocentric study was performed to compare the iStent inject® used for cataract surgery with the iStent inject® W, also used for cataract surgery. The primary stu...
Verfasser: | |
---|---|
Dokumenttypen: | Artikel |
Medientypen: | Text |
Erscheinungsdatum: | 2023 |
Publikation in MIAMI: | 29.02.2024 |
Datum der letzten Änderung: | 29.02.2024 |
Angaben zur Ausgabe: | [Electronic ed.] |
Quelle: | Journal of Clinical Medicine 12 (2023) 23, 7259, 1-9 |
Schlagwörter: | glaucoma; iStent inject; iStent inject W; intraocular pressure |
Fachgebiet (DDC): | 610: Medizin und Gesundheit |
Lizenz: | CC BY 4.0 |
Sprache: | English |
Förderung: | Finanziert durch den Open-Access-Publikationsfonds der Universität Münster. |
Format: | PDF-Dokument |
URN: | urn:nbn:de:hbz:6-47948593217 |
Weitere Identifikatoren: | DOI: 10.17879/47958470914 |
Permalink: | https://nbn-resolving.de/urn:nbn:de:hbz:6-47948593217 |
Verwandte Dokumente: |
|
Onlinezugriff: | 10.3390_jcm12237259.pdf |
We compare the short- and mid-term postoperative outcomes of the iStent inject® with its successor, the iStent inject® W. A retrospective monocentric study was performed to compare the iStent inject® used for cataract surgery with the iStent inject® W, also used for cataract surgery. The primary study endpoint was intraocular pressure (IOP) reduction six months after surgery. Six-month follow-up results were available for 35 eyes from 27 patients in the iStent inject® group and for 32 eyes from 25 patients in the iStent inject® W group. IOP reduction at six months post surgery was significantly greater in the iStent inject® W group (−2.2 mmHg [iStent inject® W] vs. −0.06 mmHg [iStent inject®], p = 0.037). There was a statistically greater decrease in glaucoma medication administration at six months in the iStent inject® group than in the iStent inject® W group (−1.28 agents vs. −0.62 agents, p = 0.007). These findings support the hypothesis that the superior positioning of the iStent inject® W (due to its larger base diameter) compared to the iStent Inject® leads to greater IOP reduction. Because of the short follow-up period, small study cohort, and differences in the number of glaucoma patients, the study results must be interpreted carefully.